ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Arbutin attenuates aluminium chloride-induced neurotoxicity and cognitive deficits in a zebrafish model of Alzheimer's disease.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Protocol for an AlClSTAR protocols · 2026Article
- Neuroprotective effects of traditional Chinese medicine using zebrafish models - a review.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by amyloid-beta plaques, tau tangles, and oxidative stress, ultimately leading to neuronal death and cognitive decline. Current treatments primarily target symptoms rather than underlying pathology, highlighting the need for novel therapeutic strategies. Arbutin, a glycoside with anti-inflammatory and antioxidant properties, remains largely unexplored in AD research. This study evaluates its neuroprotective potential in a zebrafish model of AD. Zebrafish larvae were exposed to arbutin for toxicity assessment, followed by aluminium chloride-induced cognitive impairment. Behavioural analysis (ToxTrac software), oxidative stress markers (ROS, apoptosis, lipid peroxidation, AO, 2' - 7'-DCFH-DA, and DPPP staining), and gene expression (RT-qPCR) were evaluated. Arbutin (50 µM) showed no significant morphological toxicity but improved cognitive function and reduced oxidative stress markers in AlCl
Indexed as
Identifiers
41222691What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.